Cost-Effectiveness of Landiolol, An Ultra-Short-Acting Beta-Blocker, For Prevention of Postoperative Atrial Fibrillation In Germany

Walter, E.; Schalle, K

doi:10.1016/j.jval.2017.08.1230

Value in Health

2017

DOI: 10.1016/j.jval.2017.08.1230

|View full text |Cite

Cost-Effectiveness of Landiolol, An Ultra-Short-Acting Beta-Blocker, For Prevention of Postoperative Atrial Fibrillation In Germany

E. Walter

K Schalle

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Landiolol: A Review in Tachyarrhythmias

Syed

2018

Drugs

View full text Add to dashboard Cite

Intravenous landiolol [Rapibloc (EU)], an ultra short-acting highly cardioselective β-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol has been demonstrated in a large number of randomized controlled clinical trials. Landiolol significantly reduced heart rate in patients with postoperative or intraoperative supraventricular tachycardia relative to placebo and in those with atrial fibrillation/flutter and left ventricular dysfunction relative to digoxin. It was more effective than diltiazem in converting postoperative atrial fibrillation (POAF) to normal sinus rhythm. Perioperative prophylactic administration of landiolol significantly reduced the incidence of POAF during the first week after cardiac and other surgeries, compared with diltiazem, placebo or no landiolol treatment. Landiolol also attenuated adverse haemodynamic and other responses to invasive procedures such as percutaneous coronary intervention, tracheal intubation, extubation and electroconvulsive therapy. Landiolol was generally well tolerated, with a relatively low risk of hypotension and bradycardia. Landiolol has more favourable pharmacological properties than esmolol, a short-acting β-blocker commonly used for the rapid control of heart rate. Although additional comparative studies are warranted to define the place of landiolol relative to esmolol, current evidence suggest that landiolol is a useful option for the rapid short-term control of tachyarrhythmias. Landiolol offers a simple dosage scheme and is available in two easy-to-use formulations (concentrate and powder).

show abstract

Landiolol: A Review in Tachyarrhythmias

Syed

2018

Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cost-Effectiveness of Landiolol, An Ultra-Short-Acting Beta-Blocker, For Prevention of Postoperative Atrial Fibrillation In Germany

Cited by 1 publication

References 0 publications

Landiolol: A Review in Tachyarrhythmias

Landiolol: A Review in Tachyarrhythmias

Contact Info

Product

Resources

About